Haemonetics Corporation HAE

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish second quarter fiscal year 2027 financial results at 6:00 am ET on Thursday, November 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on November 5, 2026.

Haemonetics (HAE) has been drawing investor attention after a strong total return over the past year, along with double-digit annual growth in both revenue and net income. Despite a small dip in the latest session, Haemonetics’ share price is US$108.52, with a strong 90 day share price return of 48.92% and a 1 year total shareholder return of 114.25%. This points to momentum building as investors reassess growth prospects and risk. Scan Haemonetics’ momentum against peers and uncover other...

Orchestra BioMed Holdings, Inc. (OBIO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Haemonetics and Twist Bioscience stocks surged to more than five-year highs on Thursday, as fresh growth opportunities drew cheer from Wall Street.

Exciting developments are taking place for the stocks in this article. They’ve all surged ahead of the broader market over the last month as catalysts such as new products and positive media coverage have propelled their returns.

Payment follows approximately $5 million received in January 2026, bringing total cash proceeds received to approximately $11 millionCompany remains eligible for up to approximately $10 million in additional proceeds through future revenue earnoutsMonetization of a strategic holding provides additional capital to advance Orchestra BioMed’s pivotal programs and reflects its approach to creating value through partnerships NEW HOPE, Pa., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings,

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Haemonetics (NYSE:HAE) and its peers.

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these companies face steeper challenges in scaling their businesses.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index and the State S

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.